Company Overview and News

to your dashboard

Headline News

Adocia to Continue Ultra-Rapid Insulin Development after Surprise Lilly Withdrawal

2017-01-27 genengnews
French diabetes biopharma Adocia said it will look for a new partner for Phase III development of its ultra-fast insulin product BioChaperone® Lispro following Eli Lilly’s unexpected withdrawal from the firms’ existing collaboration and license agreement. Adocia expressed disappointment and surprise that Eli Lilly had pulled out of the potentially $570 million collaboration, signed in December 2014, to develop a BioChaperone-formulated product based on Lilly’s insulin lispro Humalog®.